Meeting highlights from the CHMP meeting in September 2016
Ten medicines recommended for approval, including three medicines for cancer
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended ten medicines for approval at its September meeting.
The CHMP recommended granting a conditional marketing authorisation for Lartruvo (olaratumab) for the treatment of adults with advanced soft tissue sarcoma. Lartruvo is to be used in combination with doxorubicin (a chemotherapy medicine) in patients with advanced soft tissue sarcoma for whom surgery or radiotherapy is not suitable, and who have not been previously treated with doxorubicin. Lartruvo was reviewed under EMA’s accelerated assessment mechanism and has an orphan designation.
The Committee recommended granting a marketing authorisation for Ibrance (palbociclib) for the treatment of women with locally-advanced or metastatic breast cancer. Ibrance is to be used to treat breast cancer that is hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative.
The CHMP recommended granting a conditional marketing authorisation for Ninlaro (ixazomib) for the treatment of multiple myeloma. This follows a re-examination of the Committee’s earlier negative opinion. Ninlaro is a new medicine that is taken orally to treat multiple myeloma, and it has an orphan designation.
Glyxambi (empagliflozin/linagliptin) was recommended for approval for the treatment of type 2 diabetes.
Parsabiv (etelcalcetide) was recommended for approval for the treatment of secondary hyperparathyroidism.
One hybrid application, Chenodeoxycholic acid sigma-tau (chenodeoxycholic acid), received a positive opinion from the CHMP for the treatment of cerebrotendinous xanthomatosis. Hybrid applications rely in part on the results of pre-clinical tests and clinical trials for a reference product and in part on new data. This medicine has an orphan designation.
Four generic medicines were recommended for approval by the Committee: Ivabradine JensenR (ivabradine) and Ivabradine Zentiva (ivabradine) to treat angina pectoris and heart failure, Emtricitabine/Tenofovir disoproxil Zentiva (emtricitabine/tenofovir disoproxil) to treat HIV infection and Granpidam (sildenafil) for the treatment of patients with pulmonary arterial hypertension.
Two recommendations on extensions of therapeutic indications
The Committee recommended extensions of indications for NovoRapid and Stelara.
Outcome of review of compliance with good manufacturing practice (GMP) at Pharmaceutics International
The CHMP recommended that medicines manufactured by Pharmaceutics International Inc., located in the United States, should no longer be available in the European Union, except Ammonaps (sodium phenylbutyrate), which is used to treat a rare disease and is considered critical for public health. The recommendation is the outcome of a review into issues with GMP at Pharmaceutics International Inc.
Withdrawals of applications
The application for a marketing authorisation for Cokiera (dasabuvir/ombitasvir/paritaprevir/ritonavir) has been withdrawn, as well as a request to extend the indication of Adempas (riociguat).
More information on the CHMP's September 2016 meeting can be found on EMA's website.